Authors

Jason Zhu, MD

Latest:

Dr. Zhu on Treatment Strategies for Node-Positive Prostate Cancer

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Jonathan Spicer, MD, PhD

Latest:

Dr Spicer on Surgical Considerations After Approval of Perioperative Nivolumab in Resectable NSCLC

Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.

David B. Zhen, MD

Latest:

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

Joshi Alumkal, MD

Latest:

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Daniel Rotroff, PhD

Latest:

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

Andrew Lim, MD

Andrew Lim, MD, is a radiation oncologist with Keck Medicine of USC.

Latest:

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

Rita Assi, MD

Latest:

The Future of CAR T-Cell Therapy in R/R DLBCL: Closing Reflections and Key Takeaways

Experts discuss the future outlook for chimeric antigen receptor T-cell therapy (CAR T) in diffuse large B-cell therapy (DLBCL), exploring potential advancements and evolving treatment strategies.

LSU LCMC Health Cancer Center

Latest:

IIT Madras partners with LSU Health New Orleans, US, to Accelerate Global Health Innovation

The collaboration blends LSU Health New Orleans’s robust research capabilities with IIT Madras’ technology innovation to drive global health impact.

Mostafa Nasr, PhD candidate, Moffitt Cancer Center

Latest:

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Katherine C. Ansley, MD

Katherine C. Ansley, MD, is an associate professor in the Section of Hematology and Oncology in the Department of Internal Medicine at Wake Forest University School of Medicine and a breast cancer leader at Atrium Health Wake Forest Baptist Hematology and Oncology - Cancer Center.

Latest:

Dr Ansley on the Role of Elacestrant in ER+/HER2– Advanced Breast Cancer

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Sarbajit Mukherjee, MD, MS

Latest:

Investigators Seek Simpler Solution to Treatment Resistance in Esophageal Cancer

Although the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.

Bassam Sonbol, MD

Latest:

Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal Cancers

Mohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.

Manali Kamdar, MD

Manali Kamdar, MD, is an associate professor of Medicine-Hematology and the clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus in Aurora.

Latest:

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Lakshmi Nayak, MD

Lakshmi Nayak, MD, is the director of the Center for Central Nervous System Lymphoma and a senior physician at Dana-Farber Cancer Institute. She is also an associate professor of neurology at Harvard Medical School.

Latest:

Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Lori Muffly, MD

Lori Muffly, MD, is an associate professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford Medicine.

Latest:

Dr Muffly on the Role of Obe-Cel in R/R B-Cell Precursor ALL

Dipenkumar Modi, MD

Latest:

Dr. Modi on the Utility of BTK Inhibitors in CLL

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Gabriel Hortobagyi, MD, MACP, FASCO

Latest:

Advances Treating HR+ Metastatic Breast Cancer

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Victor Moreno, MD, PhD

Latest:

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

Deepa Jagadeesh, MD

Latest:

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Peter Kozuch, MD

Latest:

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.